| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 219.77% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/10/2023 | 423.26% | Wedbush | → $18 | Reiterates | → Outperform |
| 03/28/2023 | 219.77% | HC Wainwright & Co. | $10 → $11 | Maintains | Buy |
| 10/20/2022 | 190.7% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 09/20/2021 | 626.74% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 09/07/2021 | 365.12% | Guggenheim | → $16 | Initiates Coverage On | → Buy |
| 09/07/2021 | 481.4% | Wedbush | → $20 | Initiates Coverage On | → Outperform |
| 09/07/2021 | 394.19% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
What is the target price for Tango Therapeutics (TNGX)?
The latest price target for Tango Therapeutics (NASDAQ: TNGX) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $11.00 expecting TNGX to rise to within 12 months (a possible 219.77% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tango Therapeutics (TNGX)?
The latest analyst rating for Tango Therapeutics (NASDAQ: TNGX) was provided by HC Wainwright & Co., and Tango Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Tango Therapeutics (TNGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tango Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tango Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Tango Therapeutics (TNGX) correct?
While ratings are subjective and will change, the latest Tango Therapeutics (TNGX) rating was a reiterated with a price target of $0.00 to $11.00. The current price Tango Therapeutics (TNGX) is trading at is $3.44, which is within the analyst's predicted range.